Congenital Heart Disease (CHD) Market Report 2026

The congenital heart disease (chd) market size has grown strongly in recent years. It will grow from $4.85 billion in 2025 to $5.32 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to high prevalence of structural birth defects, limited early diagnostic capabilities, reliance on open-heart surgery, high infant mortality rates, concentration of care in tertiary hospitals.

The congenital heart disease (chd) market size is expected to see strong growth in the next few years. It will grow to $7.27 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to advancements in minimally invasive cardiology, improved imaging and diagnostics, growing adult chd population, expansion of specialized cardiac centers, rising healthcare investments. Major trends in the forecast period include growth in early prenatal and neonatal screening, rising adoption of catheter-based interventions, expansion of pediatric and adult chd care programs, increasing survival rates driving adult chd care, multidisciplinary long-term disease management.

The rising incidence of maternal diabetes is expected to support the growth of the congenital heart disease (CHD) market in the coming years. Maternal diabetes, also known as gestational diabetes mellitus (GDM), is a form of diabetes that develops during pregnancy in women without a prior history of diabetes. The condition is linked to lifestyle changes such as reduced physical activity, unhealthy eating patterns, and increasing obesity rates among women of reproductive age. Maternal diabetes can contribute to congenital heart disease (CHD) in infants, as elevated blood glucose levels can interfere with normal fetal heart development. High maternal blood sugar may disrupt cardiac formation in the fetus, increasing the likelihood of CHD. For example, in November 2025, according to the Society for Maternal Fetal Medicine, a US-based organization, gestational diabetes mellitus affected about 15.6% of women globally, with approximately 23.3 million live births impacted by hyperglycemia during pregnancy in 2024. As a result, the growing prevalence of maternal diabetes is driving expansion in the congenital heart disease (CHD) market.

Companies operating in the congenital heart disease market are increasingly focused on developing non-surgical heart valves to enhance patient outcomes and overall quality of life. Non-surgical, or transcatheter, heart valves are medical devices designed to treat heart valve conditions without the need for conventional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, reintroduced its Harmony Transcatheter Pulmonary Valve (TPV) System. This system offers a minimally invasive alternative to open-heart surgery for patients with congenital heart disease, particularly those with native or surgically repaired right ventricular outflow tract (RVOT) abnormalities. It is the first FDA-approved valve developed for the right side of the heart, providing a non-surgical option for patients with severe pulmonary valve regurgitation. The Harmony TPV System originally received US FDA approval in 2021 and was reintroduced after a voluntary recall, reflecting Medtronic’s continued commitment to advancing treatment options for congenital heart disease.

In May 2024, Novartis Healthcare Private Limited, a Switzerland-based pharmaceutical company, partnered with Ayala Healthcare Holdings, Inc. (AC Health) to launch an integrated cardiovascular and cancer care initiative. This collaboration aims to expand access to innovative treatments for conditions such as breast cancer, heart failure, and high cholesterol. Ayala Healthcare Holdings, Inc. (AC Health) is a Philippines-based pharmaceutical company that focuses on generic drug development and distribution.

Major companies operating in the congenital heart disease (chd) market are Abbott Laboratories, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Carestream Health, Schiller AG, BPL Medical Technologies, Bionet America Inc., Edwards Lifesciences Corporation, GE Healthcare, BIOTRONIK SE & Co KG, W L Gore & Associates Inc, Cook Medical, Lepu Medical Technology Co Ltd, Getinge AB, Merit Medical Systems Inc, Eurocor Tech GmbH, Braile Biomedica.

North America was the largest region in the congenital heart disease (CHD) market in 2025. The regions covered in the congenital heart disease (chd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the congenital heart disease (chd) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the congenital heart disease market by increasing costs of imported cardiac devices, diagnostic imaging equipment, surgical instruments, and consumables. Hospitals and cardiac surgery centers in North America and Europe are most affected due to dependence on imported interventional cardiology products, while Asia-Pacific faces higher costs for advanced diagnostic infrastructure. These tariffs are increasing procedural and treatment costs. However, they are encouraging local manufacturing of cardiac devices, regional supply chain development, and improved availability of essential cardiac care technologies.

The congenital heart disease (chd) market research report is one of a series of new reports that provides congenital heart disease (chd) market statistics, including congenital heart disease (chd) industry global market size, regional shares, competitors with a congenital heart disease (chd) market share, detailed congenital heart disease (chd) market segments, market trends and opportunities, and any further data you may need to thrive in the congenital heart disease (chd) industry. This congenital heart disease (chd) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Congenital heart disease (CHD) refers to a group of birth-related conditions that affect the structure and function of the heart and are present from birth. These conditions may involve the heart walls, heart valves, or the arteries and veins connected to the heart. Treatment for CHD varies based on the type and severity of the condition and can include medications, catheter-based procedures, open-heart surgery, or heart transplantation.

The primary types of congenital heart disease (CHD) include heart valve defects, heart wall defects, blood vessel defects, and others. Heart valve defects involve abnormalities or functional issues in the heart valves that control blood flow through the heart. These conditions can be diagnosed using methods such as electrocardiogram, chest X-ray, echocardiogram, transesophageal echocardiogram, pulse oximetry, exercise stress test, cardiac computed tomography (CT) scan or magnetic resonance imaging (MRI), and cardiac catheterization. Additional diagnosis and treatment approaches include interventional cardiology, cardiac surgery, telemedicine, medication management, and lifestyle modifications. The affected age groups include infants, children, adolescents, and adults, who receive care across hospitals and clinics, diagnostic centers, ambulatory surgical centers, and research and academic institutions.

The congenital heart disease (CHD) market consists of revenues earned by entities by providing services such as medical consultations, diagnostic tests, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital heart disease (CHD) market also includes sales of cardiac implants such as pacemakers, implantable cardioverter-defibrillators (ICDs), and ventricular assist devices (VADs). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.